FDA Approves Acalabrutinib with Venetoclax for CLL or SLL By Ogkologos - March 4, 2026 108 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR New on NCI’s Websites for January 2020 January 2, 2020 Zooming in: Fine-tuning the picture to diagnose oesophageal cancer earlier August 10, 2021 Mom Finding Out Baby’s Gender Uncovers Rare Condition When Doctors See... November 7, 2019 To Combat Cancer Treatment Resistance, Researchers Try Leveraging Evolution August 22, 2024 Load more HOT NEWS Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in... FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube,... For the RTOG 9408, and this randomized 1,979 patients so you... Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,...
